<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">systhiper</journal-id><journal-title-group><journal-title xml:lang="ru">Системные гипертензии</journal-title><trans-title-group xml:lang="en"><trans-title>Systemic Hypertension</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2075-082X</issn><issn pub-type="epub">2542-2189</issn><publisher><publisher-name>LLC «ИнтерМедсервис»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.26442/2075082X.2019.2.000030</article-id><article-id custom-type="elpub" pub-id-type="custom">systhiper-582</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ARTICLES</subject></subj-group></article-categories><title-group><article-title>Острая сердечная недостаточность и микроРНК</article-title><trans-title-group xml:lang="en"><trans-title>Acute heart failure and microRNA</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Насонова</surname><given-names>С. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Nasonova</surname><given-names>S. N.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Миндзаев</surname><given-names>Д. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Mindzaev</surname><given-names>D. R.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Жиров</surname><given-names>И. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Zhirov</surname><given-names>I. V.</given-names></name></name-alternatives><email xlink:type="simple">izhirov@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Терещенко</surname><given-names>С. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Tereshchenko</surname><given-names>S. N.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ «НМИЦ кардиологии»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>National Medical Research Center for Cardiology</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБУ «НМИЦ кардиологии»; ФГБОУ ДПО РМАНПО</institution><country>Россия</country></aff><aff xml:lang="en"><institution>National Medical Research Center for Cardiology; Russian Medical Academy of Continuous Professional Education</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>23</day><month>12</month><year>2022</year></pub-date><volume>16</volume><issue>2</issue><fpage>42</fpage><lpage>46</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Насонова С.Н., Миндзаев Д.Р., Жиров И.В., Терещенко С.Н., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Насонова С.Н., Миндзаев Д.Р., Жиров И.В., Терещенко С.Н.</copyright-holder><copyright-holder xml:lang="en">Nasonova S.N., Mindzaev D.R., Zhirov I.V., Tereshchenko S.N.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.syst-hypertension.ru/jour/article/view/582">https://www.syst-hypertension.ru/jour/article/view/582</self-uri><abstract><p>МикроРНК - класс некодирующих, одноцепочных РНК длиной 19-24 нуклеотидов, основной функцией которых является ингибирование экспрессии белок-кодирующих генов на посттранскрипционном уровне. Известно, что микроРНК являются важным патогенетическим звеном в развитии множества заболеваний, в том числе и сердечно-сосудистых. Разный уровень экспрессии данных молекул при различных патологиях позволяет рассматривать микроРНК в качестве потенциального диагностического и прогностического биомаркера. Многочисленные исследования подтверждают факт изменения профиля экспрессии микроРНК при сердечной недостаточности (СН). Однако подавляющее большинство этих исследований включали в себя пациентов со стабильной хронической СН, в то время как связи этих молекул с острой СН уделялось гораздо меньшее внимание. Острая СН является основной причиной госпитализации пациентов старшей возрастной группы, однако, с учетом низкой прогностической способности имеющихся биологических маркеров СН, поиск нового биологического маркера с высокой прогностической значимостью является важной задачей современной медицины. Данная статья содержит краткий обзор исследований, посвященных оценке диагностических и прогностических способностей нового потенциального биомаркера при острой СН.</p></abstract><trans-abstract xml:lang="en"><p>MicroRNA is a class of non-coding, single-stranded RNA 19-24 nucleotides in length, the main function of which is to inhibit the expression of protein-coding genes at the post-transcriptional level. It is known that microRNAs are an important pathogenetic link in the development of many diseases, including cardiovascular ones. Different levels of expression of these molecules in different pathologies make microRNAs potential diagnostic and prognostic biomarkers. Numerous studies confirm the fact of changes in the profile of microRNA expression in heart failure (HF). However, it is worth noting that the vast majority of these studies included patients with stable chronic HF, while the connection of these molecules with acute HF has received far less attention. Acute HF is the main cause of hospitalization for older patients. However, taking into account the low prognostic ability of existing biological markers of HF, the search for a new biological marker with a high prognostic significance is an important task of modern medicine. The article provides a brief overview of the research on the evaluation of diagnostic and prognostic abilities of a new potential of the biomarker in acute HF.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>острая сердечная недостаточность</kwd><kwd>микроРНК</kwd><kwd>биомаркер</kwd><kwd>диагностика</kwd><kwd>прогноз</kwd></kwd-group><kwd-group xml:lang="en"><kwd>acute heart failure</kwd><kwd>microRNA</kwd><kwd>a biomarker</kwd><kwd>diagnostics</kwd><kwd>prognosis</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Weber J.A, Baxter D.H, Zhang S et al. The microRNA spectrum in 12 body fluids. Clin Chem 2010; 56: 1733-41.</mixed-citation><mixed-citation xml:lang="en">Weber J.A, Baxter D.H, Zhang S et al. The microRNA spectrum in 12 body fluids. Clin Chem 2010; 56: 1733-41.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Romakina V.V, Zhirov I.V, Nasonova S.N et al. Micro RNA as Biomarkers of Cardiovascular Diseases: Large Opportunities of Small Molecules. Cardiology 2018; 58 (1): 66-71. DOI: 10.18087/cardio.2018.1.10083</mixed-citation><mixed-citation xml:lang="en">Romakina V.V, Zhirov I.V, Nasonova S.N et al. Micro RNA as Biomarkers of Cardiovascular Diseases: Large Opportunities of Small Molecules. Cardiology 2018; 58 (1): 66-71. DOI: 10.18087/cardio.2018.1.10083</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Givertz M.M, Teerlink J.R, Albert N.M et al. Acute decompensated heart failure: update on new and emerging evidence and directions for future research. J Card Fail 2013; 19: 371-89.</mixed-citation><mixed-citation xml:lang="en">Givertz M.M, Teerlink J.R, Albert N.M et al. Acute decompensated heart failure: update on new and emerging evidence and directions for future research. J Card Fail 2013; 19: 371-89.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Maisel A.S, Richards A.M, Pascual-Figal D, Mueller C. Serial ST2 testing in hospitalized patients with acute heart failure. Am J Cardiol 2015; 115: 32B-37B.</mixed-citation><mixed-citation xml:lang="en">Maisel A.S, Richards A.M, Pascual-Figal D, Mueller C. Serial ST2 testing in hospitalized patients with acute heart failure. Am J Cardiol 2015; 115: 32B-37B.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Pascual-Figal D.A, Caballero L, Sanchez-Mas J, Lax A. Prognostic markers for acute heart failure. Expert Opin Med Diagn 2013; 7: 379-92.</mixed-citation><mixed-citation xml:lang="en">Pascual-Figal D.A, Caballero L, Sanchez-Mas J, Lax A. Prognostic markers for acute heart failure. Expert Opin Med Diagn 2013; 7: 379-92.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Ouwerkerk W, Voors A.A, Zwinderman A.H. Factors influencing the predictive power of models for predicting mortality and/or heart-failure hospitalization in patients with heart failure. JACC Heart Fail 2014; 2: 429-36.</mixed-citation><mixed-citation xml:lang="en">Ouwerkerk W, Voors A.A, Zwinderman A.H. Factors influencing the predictive power of models for predicting mortality and/or heart-failure hospitalization in patients with heart failure. JACC Heart Fail 2014; 2: 429-36.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Rahimi K, Bennett D, Conrad N et al. Risk prediction in patients with heart failure. JACC Heart Fail 2014; 2: 440-6.</mixed-citation><mixed-citation xml:lang="en">Rahimi K, Bennett D, Conrad N et al. Risk prediction in patients with heart failure. JACC Heart Fail 2014; 2: 440-6.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37: 2129-200.</mixed-citation><mixed-citation xml:lang="en">ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37: 2129-200.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Bayés-Genis A, Lanfear D.E, de Ronde M.W.J et al. Pinto: Prognostic value of circulating microRNAs on heart failure-related morbidity and mortality in two large diverse cohorts of general heart failure patient. Eur J Heart Fail 2018; 20: 67-75.</mixed-citation><mixed-citation xml:lang="en">Bayés-Genis A, Lanfear D.E, de Ronde M.W.J et al. Pinto: Prognostic value of circulating microRNAs on heart failure-related morbidity and mortality in two large diverse cohorts of general heart failure patient. Eur J Heart Fail 2018; 20: 67-75.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Kochetov A.G, Lyang O.V, Gimadiev R.R et al. Expression of circulating microRNA in chronic heart failure in patients with cardiovascular pathologies. Lab Serv 2016; 1: 26-32. DOI: 10.17116/labs20165126-32</mixed-citation><mixed-citation xml:lang="en">Kochetov A.G, Lyang O.V, Gimadiev R.R et al. Expression of circulating microRNA in chronic heart failure in patients with cardiovascular pathologies. Lab Serv 2016; 1: 26-32. DOI: 10.17116/labs20165126-32</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Masson S, Batkai S, Beermann J et al. Circulating microRNA-132 levels improve risk prediction for heart failure hospitalization in patients with chronic heart failure. Eur J Heart Failure 2018; 20: 78-85.</mixed-citation><mixed-citation xml:lang="en">Masson S, Batkai S, Beermann J et al. Circulating microRNA-132 levels improve risk prediction for heart failure hospitalization in patients with chronic heart failure. Eur J Heart Failure 2018; 20: 78-85.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Tijsen A.J, Creemers E.E, Moerland P.D et al. MiR423-5p as a circulating biomarker for heart failure. Circ Res 2010; 106: 1035-9.</mixed-citation><mixed-citation xml:lang="en">Tijsen A.J, Creemers E.E, Moerland P.D et al. MiR423-5p as a circulating biomarker for heart failure. Circ Res 2010; 106: 1035-9.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Ellis K.L, Cameron V.A, Troughton R.W et al. Circulating microRNAs as candidate markers to distinguish heart failure in breathless patients. Eur J Heart Fail 2013; 15: 1138-47.</mixed-citation><mixed-citation xml:lang="en">Ellis K.L, Cameron V.A, Troughton R.W et al. Circulating microRNAs as candidate markers to distinguish heart failure in breathless patients. Eur J Heart Fail 2013; 15: 1138-47.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Seronde M.F, Vausort M, Gayat E.J et al. GREAT Network. Circulating microRNAs and outcome in patients with acute heart failure. PLoS One 2015; 10: e0142237.</mixed-citation><mixed-citation xml:lang="en">Seronde M.F, Vausort M, Gayat E.J et al. GREAT Network. Circulating microRNAs and outcome in patients with acute heart failure. PLoS One 2015; 10: e0142237.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Bruno N, ter Maaten J.M, Ovchinnikova E.S et al. MicroRNAs relate to early worsening of renal function in patients with acute heart failure. Int J Cardiol 2016; 203: 564-9.</mixed-citation><mixed-citation xml:lang="en">Bruno N, ter Maaten J.M, Ovchinnikova E.S et al. MicroRNAs relate to early worsening of renal function in patients with acute heart failure. Int J Cardiol 2016; 203: 564-9.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Ovchinnikova E.S, Schmitter D, Vegter E.L et al. Signature of circulating microRNAs in patients with acute heart failure. Eur J Heart Fail 2016; 18: 414-23.</mixed-citation><mixed-citation xml:lang="en">Ovchinnikova E.S, Schmitter D, Vegter E.L et al. Signature of circulating microRNAs in patients with acute heart failure. Eur J Heart Fail 2016; 18: 414-23.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Vegter E.L, Schmitter D, Hagemeijer Y et al. Use of biomarkers to establish potential role and function of circulating microRNAs in acute heart failure. Int J Cardiol 2016; 224: 231-9.</mixed-citation><mixed-citation xml:lang="en">Vegter E.L, Schmitter D, Hagemeijer Y et al. Use of biomarkers to establish potential role and function of circulating microRNAs in acute heart failure. Int J Cardiol 2016; 224: 231-9.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Vegter E.L, van der Meer P, Voors A.A. Associations between volume status and circulating microRNAs in acute heart failure. Eur J Heart Fail 2017; 19 (8): 1077-8.</mixed-citation><mixed-citation xml:lang="en">Vegter E.L, van der Meer P, Voors A.A. Associations between volume status and circulating microRNAs in acute heart failure. Eur J Heart Fail 2017; 19 (8): 1077-8.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Melman Y.F, Shah R, Danielson K et al. Circulating MicroRNA-30d Is Associated With Response to Cardiac Resynchronization Therapy in Heart Failure and Regulates Cardiomyocyte Apoptosis: A Translational Pilot Study. Circulation 2015; 131: 2202-16.</mixed-citation><mixed-citation xml:lang="en">Melman Y.F, Shah R, Danielson K et al. Circulating MicroRNA-30d Is Associated With Response to Cardiac Resynchronization Therapy in Heart Failure and Regulates Cardiomyocyte Apoptosis: A Translational Pilot Study. Circulation 2015; 131: 2202-16.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Xiao J, Gao R, Bei Y et al. Circulating miR-30d predicts survival in patients with acute heart failure. Cell Physiol Biochem 2017; 41: 865-74.</mixed-citation><mixed-citation xml:lang="en">Xiao J, Gao R, Bei Y et al. Circulating miR-30d predicts survival in patients with acute heart failure. Cell Physiol Biochem 2017; 41: 865-74.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Van Boven N, Kardys I, van Vark L.C et al. Serially measured circulating microRNAs and adverse clinical outcomes in patients with acute heart failure. Eur J Heart Fail 2018; 20: 89-96.</mixed-citation><mixed-citation xml:lang="en">Van Boven N, Kardys I, van Vark L.C et al. Serially measured circulating microRNAs and adverse clinical outcomes in patients with acute heart failure. Eur J Heart Fail 2018; 20: 89-96.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Жиров И.В., Кочетов А.Г., Засеева А.В. и др. МикроРНК в диагностике хронической сердечной недостаточности: состояние проблемы и результаты пилотного исследования. Системные гипертензии. 2016; 13 (1): 39-46.</mixed-citation><mixed-citation xml:lang="en">Жиров И.В., Кочетов А.Г., Засеева А.В. и др. МикроРНК в диагностике хронической сердечной недостаточности: состояние проблемы и результаты пилотного исследования. Системные гипертензии. 2016; 13 (1): 39-46.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Goren Y, Kushnir M, Zafrir B et al. Serum levels of microRNAs in patients with heart failure. Eur J Heart Fail 2012; 14: 147-54</mixed-citation><mixed-citation xml:lang="en">Goren Y, Kushnir M, Zafrir B et al. Serum levels of microRNAs in patients with heart failure. Eur J Heart Fail 2012; 14: 147-54</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
